<p>Bioharvest Sciences, Inc. ((BHST)) 最近召开了第三季度财报电话会议。以下是会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>Bioharvest Sciences, Inc. 最近召开了财报电话会议，透露出一种平衡的情绪，尽管收入增长令人印象深刻且成功融资，但仍受到持续净亏损和运营费用上升的影响。公司展示了显著的成就，特别是在 CDMO 领域，同时也承认面临的挑战。</p>
<h2>显著的收入增长</h2>
<p>Bioharvest Sciences 报告称，总收入同比增长了 39%，达到 910 万美元。这一增长主要得益于其核心 VINIA 胶囊的持续势头以及 VINIA Inside 产品组合的成功扩展。</p>
<h2>CDMO 业务扩展</h2>
<p>公司的 CDMO 部门经历了惊人的 722% 增长，产生了 70 万美元的收入。一个显著的亮点是与 Saffron Tech 建立的新合作关系，共同开发藏红花衍生化合物，BioHarvest 保留了 25% 的所有权股份。</p>
<h2>成功的资本融资</h2>
<p>Bioharvest 成功完成了 1990 万美元的机构股权融资，使最近的总毛收入达到 3080 万美元。这次融资显著增强了公司的资产负债表。</p>
<h2>毛利率改善</h2>
<p>毛利增加了 50%，达到 560 万美元，毛利率上升至 61%。这一改善归因于制造规模的扩大和产量的提高。</p>
<h2>VINIA BloodFlow Hydration 产品发布</h2>
<p>公司推出了 VINIA BloodFlow Hydration 的早期访问版本，目标是 170 亿美元的美国电解质补水市场，标志着在新产品类别中的战略扩展。</p>
<h2>持续的净亏损</h2>
<p>尽管收入增长积极，Bioharvest 报告称 2025 年第三季度净亏损为 250 万美元，较去年同期的 270 万美元亏损略有改善。</p>
<h2>运营费用增加</h2>
<p>运营费用从 580 万美元上升至 650 万美元，主要由于市场营销支出和 Health Pros 会员计划的开发成本增加。</p>
<h2>前瞻性指导</h2>
<p>展望未来，Bioharvest Sciences 预计第四季度收入将在 900 万至 950 万美元之间，调整后的 EBITDA 接近盈亏平衡。公司旨在扩大其直销和 CDMO 业务，得益于增强的资产负债表和不断增长的美国 VINIA 活跃用户基础。</p>
<p>总之，Bioharvest Sciences 的财报电话会议反映出一种平衡的情绪，收入增长和融资方面的显著成就，与净亏损和费用上升的挑战相抵消。公司对未来前景持乐观态度，战略扩展和财务强化为潜在盈利铺平了道路。</p>

BHST

<p>BioHarvest Sciences 报告称，收入增长了 39%，达到 910 万美元，主要得益于 VINIA 产品。CDMO 部门增长了 722%，产生了 70 万美元的收入。1990 万美元的股权融资增强了资产负债表。毛利润增长了 50%，达到 560 万美元，利润率为 61%。尽管净亏损为 250 万美元，运营费用增加至 650 万美元。公司预计第四季度收入将在 900 万至 950 万美元之间，并力争实现 EBITDA 盈亏平衡，专注于直接面向消费者和 CDMO 扩张</p>

<p>Bioharvest Sciences, Inc. ((BHST)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Bioharvest Sciences, Inc. ((BHST)) 最近召开了第三季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>Bioharvest Sciences, Inc. recently held its earnings call, revealing a balanced sentiment marked by impressive revenue growth and successful capital raising, yet tempered by ongoing net losses and rising operating expenses. The company showcased significant achievements, particularly in the CDMO segment, while also acknowledging the challenges it faces.</p>
<div class="lb-trans"><p>Bioharvest Sciences, Inc. 最近召开了财报电话会议，透露出一种平衡的情绪，尽管收入增长令人印象深刻且成功融资，但仍受到持续净亏损和运营费用上升的影响。公司展示了显著的成就，特别是在 CDMO 领域，同时也承认面临的挑战。</p>
</div><h2>Significant Revenue Growth</h2>
<div class="lb-trans"><h2>显著的收入增长</h2>
</div><p>Bioharvest Sciences reported a remarkable 39% year-over-year increase in total revenues, reaching $9.1 million. This growth was primarily driven by the sustained momentum of its core VINIA capsules and the expanding success of the VINIA Inside product portfolio.</p>
<div class="lb-trans"><p>Bioharvest Sciences 报告称，总收入同比增长了 39%，达到 910 万美元。这一增长主要得益于其核心 VINIA 胶囊的持续势头以及 VINIA Inside 产品组合的成功扩展。</p>
</div><h2>CDMO Business Expansion</h2>
<div class="lb-trans"><h2>CDMO 业务扩展</h2>
</div><p>The company’s CDMO segment experienced a staggering 722% growth, generating $0.7 million in revenue. A notable highlight was the new partnership with Saffron Tech to develop saffron-derived compounds, with BioHarvest retaining a 25% ownership stake.</p>
<div class="lb-trans"><p>公司的 CDMO 部门经历了惊人的 722% 增长，产生了 70 万美元的收入。一个显著的亮点是与 Saffron Tech 建立的新合作关系，共同开发藏红花衍生化合物，BioHarvest 保留了 25% 的所有权股份。</p>
</div><h2>Successful Capital Raise</h2>
<div class="lb-trans"><h2>成功的资本融资</h2>
</div><p>Bioharvest successfully completed a $19.9 million institutional equity financing, bringing total gross proceeds from recent efforts to $30.8 million. This capital raise has significantly strengthened the company’s balance sheet.</p>
<div class="lb-trans"><p>Bioharvest 成功完成了 1990 万美元的机构股权融资，使最近的总毛收入达到 3080 万美元。这次融资显著增强了公司的资产负债表。</p>
</div><h2>Gross Profit Margin Improvement</h2>
<div class="lb-trans"><h2>毛利率改善</h2>
</div><p>Gross profit increased by 50% to $5.6 million, with gross margins rising to 61%. This improvement was attributed to increased manufacturing scale and improved yields.</p>
<div class="lb-trans"><p>毛利增加了 50%，达到 560 万美元，毛利率上升至 61%。这一改善归因于制造规模的扩大和产量的提高。</p>
</div><h2>VINIA BloodFlow Hydration Launch</h2>
<div class="lb-trans"><h2>VINIA BloodFlow Hydration 产品发布</h2>
</div><p>The company launched an early access rollout of VINIA BloodFlow Hydration, targeting the $17 billion U.S. electrolyte hydration market, marking a strategic expansion into new product categories.</p>
<div class="lb-trans"><p>公司推出了 VINIA BloodFlow Hydration 的早期访问版本，目标是 170 亿美元的美国电解质补水市场，标志着在新产品类别中的战略扩展。</p>
</div><h2>Continued Net Losses</h2>
<div class="lb-trans"><h2>持续的净亏损</h2>
</div><p>Despite the positive revenue growth, Bioharvest reported net losses of $2.5 million for Q3 2025, a slight improvement from the $2.7 million loss in the same quarter of the previous year.</p>
<div class="lb-trans"><p>尽管收入增长积极，Bioharvest 报告称 2025 年第三季度净亏损为 250 万美元，较去年同期的 270 万美元亏损略有改善。</p>
</div><h2>Increased Operating Expenses</h2>
<div class="lb-trans"><h2>运营费用增加</h2>
</div><p>Operating expenses rose to $6.5 million from $5.8 million, driven by increased marketing spend and development costs for the Health Pros affiliate program.</p>
<div class="lb-trans"><p>运营费用从 580 万美元上升至 650 万美元，主要由于市场营销支出和 Health Pros 会员计划的开发成本增加。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Bioharvest Sciences anticipates fourth-quarter revenues between $9 million and $9.5 million, with adjusted EBITDA nearing breakeven. The company aims to expand its direct-to-consumer and CDMO operations, supported by a strengthened balance sheet and a growing U.S. VINIA active user base.</p>
<div class="lb-trans"><p>展望未来，Bioharvest Sciences 预计第四季度收入将在 900 万至 950 万美元之间，调整后的 EBITDA 接近盈亏平衡。公司旨在扩大其直销和 CDMO 业务，得益于增强的资产负债表和不断增长的美国 VINIA 活跃用户基础。</p>
</div><p>In summary, Bioharvest Sciences’ earnings call reflected a balanced sentiment with notable achievements in revenue growth and capital raising, offset by challenges of net losses and rising expenses. The company remains optimistic about its future prospects, with strategic expansions and financial fortification paving the way for potential profitability.</p>
<div class="lb-trans"><p>总之，Bioharvest Sciences 的财报电话会议反映出一种平衡的情绪，收入增长和融资方面的显著成就，与净亏损和费用上升的挑战相抵消。公司对未来前景持乐观态度，战略扩展和财务强化为潜在盈利铺平了道路。</p>
</div>

BioHarvest Sciences 报告了平衡的财报电话会议见解